Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer (PGx-SELECT)

This study has been withdrawn prior to enrollment.
(Investigator decided it was not feasible to conduct this study)
Sponsor:
Information provided by:
Georgetown University
ClinicalTrials.gov Identifier:
NCT00881114
First received: April 13, 2009
Last updated: August 18, 2009
Last verified: April 2009

April 13, 2009
August 18, 2009
April 2009
June 2009   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: 36months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00881114 on ClinicalTrials.gov Archive Site
  • Objective response [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 36 months ] [ Designated as safety issue: No ]
  • Toxicity [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
  • Quality of Life [ Time Frame: 36 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer
A Prospective Phase II Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

This is a study for patients with head and neck cancer who will be receiving chemotherapy and radiation therapy for their disease. The purpose of this study is to see if the investigators can use genetic differences between patients to select the right drug to use with radiation therapy. This type of genetic testing is called pharmacogenetics.

Currently there are two drugs used to treat head and neck cancer that have provided a benefit when given with radiation compared to radiation alone in previous studies. These two drugs are cisplatin and cetuximab (Erbitux).

In this trial, the investigators will test whether genetic differences between patients can be used to pick which drug they should receive. A recent study that looked back to see how well patients with head and neck cancer responded to treatment with cisplatin showed that genetic differences in a few genes were associated with who did and who did not survive their cancer. The investigators are taking that finding and using it to test patients for these genetic differences to determine whether they should receive cisplatin or cetuximab. In other words, the investigators are trying to take what is essentially a flip of the coin choice between these two drugs, and instead use individual patient's genetic differences to make-and hopefully improve- this choice.

Treatment-naive patients with locally advanced, non-metastatic (Stage III to IVB) squamous cell carcinoma of the head and neck who are candidates for concurrent chemoradiotherapy as primary therapy with curative intent will be enrolled. Patients will be genotyped for variations at four SNP loci in 3 genes involved in DNA nucleotide excision repair (ERCC1, ERCC2, and XRCC1). Patients with 3 to 8 variants will receive cisplatin, while patients with 2 or fewer variants will receive cetuximab.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Head and Neck Cancer
  • Drug: Cisplatin
    Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
    Other Names:
    • cis-diamminedichloridoplatinum(II)
    • CDDP
  • Drug: Cetuximab
    Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
    Other Name: Erbitux
  • Experimental: Cetuximab
    patients with 2 or fewer genetic variants will receive cetuximab
    Intervention: Drug: Cetuximab
  • Experimental: Cisplatin
    Subjects with 3 to 8 genetic variants will receive cisplatin
    Intervention: Drug: Cisplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
96
June 2013
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Biopsy proven squamous cell carcinoma of the head and neck, including of the oral cavity, oropharynx, hypopharynx, or larynx
  • Locally advanced, Stage III or IVB disease and a candidate for primary therapy using chemotherapy and radiation with curative intent
  • Patients with a diagnosis of 'unknown primary' will be eligible if chemoradiotherapy is primary modality of treatment
  • No previous chemotherapy, radiation, or surgery for the diagnosis of head and neck cancer
  • ECOG performance status 0 or 1
  • Negative pregnancy test
  • Hemoglobin >/= 8.0
  • Absolute neutrophil count >/= 1500
  • Platelet count >/= 100,000
  • GFR > 50 mL/min
  • Total bilirubin </= 1.5 upper limits of normal
  • AST and ALT </= 2.5 times upper limits of normal
  • No other current malignancy, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular in situ of the breast.
  • Ability and willingness to give consent
  • Subjects must in the opinion of the Investigator be capable of complying with the protocol

Exclusion Criteria:

  • Primary tumors of the nasopharynx, sinuses, and salivary glands
  • Acute treatment for an infection or other serious medical illness within 14 days prior to study entry
  • Major surgery within 3 weeks prior to study entry
  • Known hypersensitivity to cisplatin or cetuximab
  • Patients who have any severe or uncontrolled medical conditions or other conditions that could affect their participation in this study including: unstable angina, serious uncontrolled cardiac arrhythmia, active or uncontrolled infectious disorder, myocardial infarction </= 6 months prior to study entry
  • Psychiatric illness that would limit compliance with study requirements
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00881114
PGx-SELECT, 2008-526
Yes
John Deeken, MD, Georgetown University Medical Center
Georgetown University
Not Provided
Principal Investigator: John Deeken, MD Georgetown University
Georgetown University
April 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP